Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
As2O3 versus As4S4 for newly diagnosed acute promyelocytic leukemia
ChiCTR-TRC-09000537Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of arsenic trioxide and arsenic tetrasulfide in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: disease-free survival and overall survival. Started Sep 2009; status: completed.
02
Drugs
arsenic trioxidearsenic tetrasulfide
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-TRC-09000537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000537.